Following the recommendations of the World Health Organization (WHO), the United Nations Drugs Committee (CND) decided to place five new psychoactive substances and one drug under international control.
Recommendations were developed by the Committee of Experts on Drug Dependence-ECDD, which consists of global experts who analyze the health risks and benefits of psychoactive substances in the world markets and warning that they can use them to use their use of in countries.
These substances have come to his attention who is illegal constructed, posing a serious risk to public health and society without any recognized therapeutic use. We are pleased that the Commission (for drugs) has accepted the complete set of its recommendations and added these substances to relevant timetables in the 1961 or 1971 contracts. We hope that countries and communities will increase the vigilance and take the necessary actions to protect them.
Dr. Deus Mubangizi, Director of Policy and Product Health Standards
Four substances placed on Program I of the Single Drugs Agreement (1961), as amended by the 1972 protocol is:
- Protonitzen N-PyrrolidinIt is also referred to as Protonitazepyne, is a synthetic opioid. It has been described as beige powder or white colorless or crystalline solid and has been identified on misleading opioids. It is said to be administered by various routes, such as smoking, snorting and infusion. Can cause significant damage, including death. It has no known therapeutic use.
- RenoothIt is also referred to as Metonitazepyne, is a synthetic opioid. It has been described as a beige powder and is reported to be administered by injection. There is evidence that its use causes significant damage, including death. It has no known therapeutic use.
- EtonitazepipneIt is also referred to as N-Epiridinyl Etonitazne, is a synthetic opioid. It has been described as a crystalline solid and yellow-white or yellow powder. There is evidence that the use of this substance causes significant damage, including death. It has no known therapeutic use.
- Isotitazen n-farely; It is also referred to as Norisotonitazne, it is a synthetic opioid described as a crystalline solid. It has been detected in falsified medicinal products. Many hospital deaths and admissions have been reported in at least two areas. There is evidence that its use causes significant damage, including death. It has no known therapeutic use.
Substance placed in program II of the contract for psychotropic substances (1971):
- ExtramanavinolAlso known as HHC, it is a semi-synthetic cannabinoid described as colorless viscosity or resin. Products such as flowers and cannabis resins THC injected or sprayed with substance, electronic fluids and electronic cigarettes cartridges, edible products such as gummies and marshmallows, tinctures that look like nutritional supplements and distillation may include HHC. There is sufficient indications that HHC is used in ways to constitute a public health and social problem, justifying the placement under international control.
Substance placed in the IV program of the contract for psychotropic substances (1971):
- Kimaoprool is A centrally active skeletal muscle. Carisoprodol is available as a medicinal product in tablet, detected in misleading medicinal products and is also as white dust. There is increasing evidence that non -medical use of Carisoprodol in some countries is a significant risk to public health.
Which has concealed ECDD as a scientific advisory body for over 70 years with the mission of protecting populations from harmful substances and ensuring that psychoactive substances are available when needed for medical and scientific purposes. ECDD is conducting scientific revisions at the request of the United Nations Drugs Committee and is the only body to infringe the Treaty to provide health recommendations to the Commission to inform decisions on drug policy.
With the continued appearance of more harmful substances, including secret synthetic opioids, without medical use such as fentanyl and nitazenia, the Member States expressed interest in more scientific revisions of these substances from which the following period. The aforementioned decisions were announced at 68th A regular meeting of the drug committee, held in Vienna, Austria, on March 10-14, 2025.
